AUR-AERX-TTM1-A-1-1-R-A742-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.450
- MYC_TARGETS_V1+0.430
- E2F_TARGETS+0.380
- G2M_CHECKPOINT+0.340
- DNA_REPAIR+0.270
- PEROXISOME+0.250
- MTORC1_SIGNALING+0.240
- PROTEIN_SECRETION+0.210
- UNFOLDED_PROTEIN_RESPONSE+0.210
- SPERMATOGENESIS+0.150
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.530
- IL6_JAK_STAT3_SIGNALING-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- INTERFERON_ALPHA_RESPONSE-0.510
- INTERFERON_GAMMA_RESPONSE-0.510
- INFLAMMATORY_RESPONSE-0.480
- TNFA_SIGNALING_VIA_NFKB-0.480
- WNT_BETA_CATENIN_SIGNALING-0.430
- KRAS_SIGNALING_UP-0.400
- UV_RESPONSE_DN-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R6 | — | — | 0.932 |
| 2 | BSR_04_0040_A3_S71 | — | B | 0.924 |
| 3 | 20120289.LumB | — | B | 0.913 |
| 4 | TCGA-B6-A0X5-01A-21R-A109-07 | — | B | 0.910 |
| 5 | 20040104.LumB | — | B | 0.906 |
| 6 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.905 |
| 7 | SRR8613751 | — | C | 0.903 |
| 8 | BS_VA5T4KAA | medulloblastoma | — | 0.899 |
| 9 | SRR4195684 | — | — | 0.898 |
| 10 | AUR-AG12-TTM1-A-1-1-R-A743-41 | — | C | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.040 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |